AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04754607 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Description: Eight target points (superior, mediolateral, inferior border of the right and left thyroid lobes, right and left sides of the isthmus) will be marked with a surgical pen by determining the thyroid borders on the skin by thyroid ultrasonography by the specialist physician. Low-level laser (28.57 J / cm2) fixed applications will be made on the thyroid gland, approximately 1 cm from each other. In practice, the patient's neck will be maintained in the extension position. Each application will last 20 seconds and the radiant energy will be 2 J, the tip of the laser will be kept in contact with the skin and upright. Duration of treatment is 6 sessions 2 days a week. The cumulative dose will be 96 J.
Study NCT04754607 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Probes were placed in the sham laser group in a similar way as in the treatment group. The screen of the laser device was active; however, the energy was set as 0 J and the power as 0 mW , respectively,and the same operations were also performed.
Study NCT05460325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Lanadelumab subcutaneous injection
Study NCT05261178 — intervention group
Intervention type: OTHER
Intervention: Evaluation of satisfaction and the level of daily living activities using the prosthesis
Description: Evaluation of satisfaction with using the prosthesis with TAPES (Trinity Amputation and Prosthesis Experience Scale) and the level of daily living activities using the prosthesis with SF-36 (Short Form-36)
Study NCT06670872 — intervention group
Intervention type: DRUG
Intervention: Eravacycline combination therapy group
Description: Physicians determine the combination regimen of eravacycline, which may include sulbactam or compound preparations containing sulbactam, polymyxin B, beta-lactam antibiotics, etc., based on the pathogen identification and susceptibility results, and the China Guidelines for Diagnosis, Treatment, and Prevention of Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria. The combined drugs are used according to their instructions for use or clinical practice guidelines.
Study NCT06203106 — intervention group
Intervention type: OTHER
Intervention: Biological Sample Collection
Description: Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
Study NCT06616831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Transcutaneous Auricular Vagal Nerve Stimulation Paired with Task-Specific Training
Description: Each participant will complete 2 weeks, 3 times per week, task-specific training paired with transcutaneous auricular vagal nerve stimulation.
Study NCT06621238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Listen to Music
Study NCT04739813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study NCT04739813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study NCT04739813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: administered orally, days 1 and 14, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study NCT04739813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polatuzumab
Description: administered intravenously, on day 2, at varying doses of 1.4-1.8 mg/kg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study NCT04739813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study NCT04739813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: administered orally, days 2-14, at a dose of 800 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study NCT05499221 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carriere motion appliance
Description: The CMA will be bonded on the permanent maxillary canine and first molar, and the correct size is chosen according to the manufacturer's instructions.
Study NCT05499221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carriere motion appliance
Description: The CMA will be bonded on the permanent maxillary canine and first molar, and the correct size is chosen according to the manufacturer's instructions.
Study NCT05092191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis oil vs placebo
Description: Eligibility, Screening and Baseline (T0):~Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .~Follow-up visits:~Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.~At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.~Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being.
Study NCT05092191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis oil vs placebo
Description: Eligibility, Screening and Baseline (T0):~Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .~Follow-up visits:~Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.~At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.~Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being.
Study NCT04508699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semantic learning
Description: Experimental semantic learning from linguistic context task
Study NCT04508699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: semantic learning
Description: Experimental semantic learning from linguistic context task
Study NCT06626412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Test: 18F-SynVesT-1 PET
Description: Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 18F-SynVesT-1.
Study NCT06626412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Test: 18F-SynVesT-1 PET
Description: Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 18F-SynVesT-1.
Study NCT06626412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Volumetric MRI
Description: Magnetic resonance imaging of brain volume.
Study NCT06626412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Volumetric MRI
Description: Magnetic resonance imaging of brain volume.
Study NCT04981678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine
Description: Patients randomized to this group will reduce their buprenorphine dose prior to surgery.
Study NCT04981678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine
Description: Patients randomized to this group will continue their buprenorphine at the full prescribed dose.
Study NCT06720051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraosseous dexamethasone injection after 3rd molar surgery
Description: In Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing
Study NCT06720051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submucosal dexamethasone injection after 3rd molar surgery
Description: In Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery.
Study NCT06724068 — intervention group
Intervention type: OTHER
Intervention: Diabetes，Insulin resistance，Control
Description: This retrospective study uses medical records and diagnostic data from patients with type 2 diabetes and healthy controls obtained from Qianfoshan Hospital from2019 to 2022
Study NCT06722482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDBA
Description: Twenty five participants will receive FDBA in anterior extraction sockets as part of the alveolar ridge preservation procedure.
Study NCT06288165 — intervention group
Intervention type: DEVICE
Intervention: Coronary Sinus Reducer Implantation
Description: Coronary Sinus (CS) Reducer implantation to coronary sinus via the venous system. Coronary Sinus is a balloon-expandable, hourglass-shaped, scaffold implanted percutaneously into the coronary sinus creating a narrowing to delay blood outflow.
Study NCT04927754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral guidance
Description: Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. As a result, the effect of the cartoon-assisted distraction technique during dental treatment on behavior in pediatric patients was evaluated.
Study NCT06722482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CEBX
Description: Twenty five participants will receive CEBX in anterior extraction sockets as part of the alveolar ridge preservation procedure.
Study NCT05422274 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Pulse Stimulation
Description: A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on improving inattention and hyperactivity .
Study NCT05422274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Pulse Stimulation
Description: A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on improving inattention and hyperactivity .
Study NCT06732570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high intensity laser
Description: the patient will be in supine position with shoulder uncovered from clothes and wearing laser protective eye glass to protect eye from laser radiation, the dose will be selected from device pathologies list programs number thirty-four with 30% power, frequency continuous, density 16 j/cm2, time automatically adjusted by the device according to the width of scanning area ( superiorly from the acromioclavicular joint down to end of biceps tendon and medially from the coracoid process to the middle fiber of deltoid laterally) and the infrared will be ON.
Study NCT06732570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: manual therapy (mulligan shoulder abduction, deep transverse friction technique on the supraspinatus tendon, scapular mobilization, caudal and posterior humeral mobilization) three session weekly over 5 weeks.
Study NCT06732570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy
Description: manual therapy (mulligan shoulder abduction, deep transverse friction technique on the supraspinatus tendon, scapular mobilization, caudal and posterior humeral mobilization) three session weekly over 5 weeks.
Study NCT06732570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise therapy
Description: therapeutic exercises (rotator cuff strengthening, cools ex's, serratus punch supine ex, pectoralis minor flexibility (focused and gross stretch) and posterior capsule modified sleeper stretching ex's from side)
Study NCT06732570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise therapy
Description: therapeutic exercises (rotator cuff strengthening, cools ex's, serratus punch supine ex, pectoralis minor flexibility (focused and gross stretch) and posterior capsule modified sleeper stretching ex's from side)
Study NCT06733727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole pre-treatment in addition to misoprostol as medical management for silent miscarriage
Study NCT06733727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Mifepristone pre-treatment in addition to misoprostol as medical management for silent miscarriage
Study NCT06733662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Education-based motivational interviewing Group
Description: The Effect of Motivational Interviewing-Based Education on Treatment Adherence and Self-Care Agency in COPD Patients
Study NCT06733389 — intervention group
Intervention type: OTHER
Intervention: peripheral waveform collection
Description: The peripheral venous pressure is collected by connecting a pressure transducer that is currently in use to the central venous line. In addition, pulse pressure variation and stroke volume variation that can be obtained from the arterial catheter. In addition, the pleth variability index is collected through the oxygen saturation monitoring. This extracts the medical records and bio-signal information of the subjects registered through the previously approved 'Establishment of a Bio-signal and Clinical Information Registry for the Development of Patient Monitoring Algorithms' (B-2202-738-401).
Study NCT06731907 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV Infusion.
Study NCT06731907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV Infusion.
Study NCT06731907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV infusion AUC5 or 6 mg/mL•min and not exceeding 900mg.
Study NCT06731907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m\^2 IV infusion.
Study NCT06731907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100mg/m\^2 IV infusion.
Study NCT06731907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m\^2 IV infusion.
Study NCT05511701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Care Model
Description: The CHW will measure the participant's blood pressure (BP) and along with other demographic variables, calculate the participant's absolute CVD risk score, using the mHealth (mobile health) app. If the participant's risk is > 10%, they are asked to sign the informed consent. The CHW will electronically schedule an appointment at the PCC. The participant will receive a SMS appointment confirmation. S/he will have their cholesterol tested by nurses using a home POCT. Nurses will repeat POCT lipids and BP measurements at all PCC visits and other clinical information will be entered into the electronic decision support tool that will generate a guideline based treatment recommendation for the physician. CHWs will make up to four home visits or telephone calls to intervention participants over the 12 month study period to check on medication adherence, as well as to determine if the patient is in possession of the medication
Study NCT05511701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Model
Description: All study participants will be visited in their home by a CHW and a nurse for eligibility assessment, screening, and enrollment. The CHW will then measure the participant's blood pressure and the readings along with other demographic variables already collected, to calculate the participant's absolute CVD risk score. In the usual care arm the CHW will use the WHO paper-based non-lab CVD risk calculator and, if the participant's risk is > 10%, they are asked to sign the informed consent and s/he will have their cholesterol tested by nurses using POCT during a home enrollment visit. The CHW will further verbally encourage her/him to schedule an appointment with a primary care physician at the PCC for evaluation. This is the usual care practice.
Study NCT06499454 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ruby ROSE evaluation
Description: Creation and digitization of ROSE slides produced using Ruby's instrument from bronchoscopic biopsy samples
Study NCT06731907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: HER3-Dxd 5.6mg/kg IV infusion.
Study NCT06732245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NA-931
Description: NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (Zepbound) placebo
Study NCT06732245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound NA-931 Placebo (oral, daily)
Study NCT06732245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist~• Other Names:~* Mounjaro~* Zepbound~NA-931 Placebo (oral, daily)
Study NCT06732245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NA-931
Description: NA-931, an oral, daily~• A quadruple receptor agonist
Study NCT06732245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NA-931
Description: NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound
Study NCT06732245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA-931
Description: NA-931 (oral daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound
Study NCT06732245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NA-931 150 mg + no Tirzepatide
Description: NA-931 150 mg + no Tirzepatide
Study NCT06732245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NA-931
Description: NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound
Study NCT06732024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaccum assisted closure
Description: close skin and SC tissue by vaccum device
Study NCT06732024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary wound closure
Description: close skin and SC tissue by primary closure
Study NCT06733883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychotherapy
Description: Music therapy
Study NCT05451251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Implantation of deep brain stimulation lead within the pontine lesion
Study NCT06388694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Care
Description: Pharmacists will provide ADHD medication refill orders in response to secure message requests by parents, under the authorization of appropriate physicians.
Study NCT06388694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care Physician Care
Description: Primary care pediatricians will provide ADHD medication refill orders in response to secure message requests by parents. This is usual care.
Study NCT04998617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste with curcumin
Description: Subjects will be given toothpaste to be used during this study with 0.5% curcumin
Study NCT05559034 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive intervention
Description: This is a cognitive intervention consisting in the repetition according to three blocks, of cognitive tasks (Stroop and N-back tasks) at variating workload levels (low, middle and high levels). Each cognitive task will be presented for each workload level during three minutes.
Study NCT03728829 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab+TP
Description: Trastuzumab (4 mg/kg loading dose, then 2 mg/kg I.V., every week, totally 17 weeks (6 cycles)) combined with TC neoadjuvant chemotherapy (Docetaxel 75 mg/m2 I.V., day 1, Carboplatin 400 mg/kg, I.V., day 2, every 3 weeks, totally 6 cycles).